SUGAPILL-PIO
MRP: 1,290
Packaging: 10x10
Pack Type: tablet
Composition:
Vildagliptin 50mg + Pioglitazone HCI 15mg
Indication:
Type 2 Diabetes
Description:
This tablet combines Vildagliptin 50 mg, a DPP-4 inhibitor, with Pioglitazone Hydrochloride 15 mg, a thiazolidinedione class drug, to manage type 2 diabetes mellitus effectively. Vildagliptin enhances the release of insulin and decreases glucagon levels by increasing incretin hormones. Pioglitazone improves insulin sensitivity by activating PPAR-gamma receptors, thereby increasing glucose uptake in muscle and adipose tissues and decreasing glucose production by the liver.
Together, this combination targets multiple mechanisms to improve glycemic control, reduce insulin resistance, and support overall blood sugar regulation in patients inadequately controlled by monotherapy.
Tags:
- Dual action improves glycemic control
- Enhances insulin secretion and sensitivity
- Reduces blood glucose levels effectively
- Helps decrease insulin resistance
- Suitable for combination therapy in type 2 diabetes
Usage Information
Dosage
Take one tablet once daily, with or without food Follow your doctor’s advice on dosage and monitoring Regular blood glucose testing recommended
Side Effects
Weight gain and fluid retention Headache, dizziness Edema (swelling), especially in legs and ankles Possible gastrointestinal symptoms like nausea Rare: heart failure exacerbation, liver enzyme elevation
Contraindications
Type 1 diabetes or diabetic ketoacidosis Heart failure (especially NYHA class III/IV) Known hypersensitivity to Vildagliptin or Pioglitazone Active liver disease or elevated liver enzymes Pregnancy and breastfeeding unless directed by a doctor
Availability
Vildagliptin Pioglitazone combo, Vildagliptin 50mg Pioglitazone 15mg, Type 2 diabetes treatment, Insulin sensitizer, DPP-4 inhibitor tablet